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Background: Recombinant allergens are under investigation for
replacing allergen extracts in immunotherapy. Site-directed mu-
tagenesis has been suggested as a strategy to develop hypoallergenic
molecules that will reduce the risk of side effects. For decades,
chemically modified allergen extracts have been used for the same
reason.
Aim: To evaluate whether glutaraldehyde modification is a good
strategy to produce hypoallergenic recombinant allergens with re-
tained immunogenicity.
Methods: Fel d 1 was cloned as a single construct linking both
chains of the molecule and expressed in Escherichia coli and Pichia
pastoris. After physicochemical purification, recombinant (r) Fel d 1
was chemically modified using glutaraldehyde. The effect of mod-
ification on immune reactivity was evaluated using radioallergosor-
bent test, CAP inhibition, competitive radioimmunoassay, enzyme-
linked immunosorbent assay, basophil histamine release, and T-cell
proliferation assays. Both natural and recombinant unmodified Fel d
1 were used as controls.
Results: rFel d 1 demonstrated similar IgE binding and biologic
activity as its natural counterpart. Upon modification, IgE-binding
potency decreased 1000-fold, translating into a 106-fold reduc-
tion in biologic activity assessed by basophil histamine release. In
contrast, the modified recombinant did not show a decreased but
even a moderately increased capacity (1.5-fold) to stimulate prolif-
eration of T cells (P  0.01). Finally, it induced specific IgG
antibodies in rabbits that recognized the unmodified allergen.
Conclusions: Chemical modification is a practical and highly effec-
tive approach for achieving hypoallergenicity of recombinant aller-
gens with retained immunogenicity.
Key Words: allergoid, Felis domesticus, hypoallergen,
immunotherapy, rFel d 1
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It is well established that Fel d 1 is responsible for most IgEreactivity in cat-allergic patients.1–6 Treatment of cat al-
lergy by immunotherapy with epithelial extracts was demon-
strated to be effective.7,8 From a regulatory perspective,
treatment with mammalian extracts is not ideal because of the
potential risk to transmit pathogens. The dominant role of Fel
d 1 in cat allergy makes the development of a recombinant
Fel d 1–based product an obvious choice. Fel d 1, a 38-kDa
glycoprotein with N-linked olisaccharides,9 was first cloned
and expressed by Morgenstern et al.10 The allergen consists
of two 19-kDa noncovalently linked heterodimers, each com-
posed of a light -chain and a heavy -chain,10 encoded by 2
separate genes.11 Three disulfide bridges connect the -chain
and -chain in an antiparallel orientation.9,12 Expressed as
individual chains in Escherichia coli (E. coli), IgE binding
was poor,13,14 but combining both chains, followed by a
lengthy refolding protocol, a recombinant was obtained with
similar IgE reactivity as natural Fel d 1.1,14,15 More recently,
Fel d 1 was also expressed as a single construct. In baculo-
virus both chains were connected in an antiparallel fashion by
a linker sequence,16,17 whereas in E. coli, both chains were
connected in a parallel orientation without linker sequence.18
One of the disadvantages of specific immunotherapy is
the risk of anaphylactic reactions. By site-directed mutagen-
esis it is now possible to produce recombinant molecules with
reduced IgE binding, so-called hypoallergens. This approach
has been reported for several inhalant and food allergens.
Mutating 6 amino acids of Bet v 1 gave a hypoallergenic but
structurally unchanged molecule19,20 and similar results were
reported for the peanut allergens Ara h 1–3.21,22 To our
knowledge, this strategy has not yet been applied to Fel d 1.
The disadvantage of this approach is that it requires
considerable insight into the surface structure of an aller-
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gen to be able to predict which amino acids should be
mutated. Random mutagenesis may be an alternative, but
requires laborious screening protocols. Furthermore, re-
duction of IgE binding is sometimes limited and variable
for individual patients.19,22
Before the era of molecular biology, chemical modifi-
cation by, for example, glutaraldehyde or formaldehyde was
used as a way to reduce the IgE-binding potency of allergen
extracts.23 This was first described by Marsh et al.24,25 Here,
we set out to evaluate the feasibility of chemical modification
with glutaraldehyde of a recombinant allergen as an alterna-
tive to the production of a hypoallergenic mutant obtained by
site-directed mutagenesis. To this end, we expressed Fel d 1
as a single construct in a parallel orientation, in E. coli and
Pichia pastoris (P. pastoris).
MATERIALS AND METHODS
Cloning and Expression of Fel d 1
In one construct both chains (- and -chain) were
cloned together using a linker oligo26 in the pPICZA vector
(Invitrogen, San Diego). After transformation into P. pastoris
GS115 (His4) and expression in a Bioflo 3000 bench-top
fermentor, cells were harvested and the supernatant was
stored at 4°C in 0.1% azide.
A second construct was created by directly linking the
C-terminal residue of the -chain with the N-terminal residue
of the -chain in the pET-19b vector. After transformation
into E. coli BL21 (DE3) (Novagen Inc., Madison, WI) and
expression, the cell pellet was frozen overnight at 20°C,
thawed, and resuspended to one tenth of the original culture
volume in 25 mM Tris/2 mM EDTA/pH 7.6. After sonication
and pelleting of insoluble matter by centrifugation, the su-
pernatant was saved for further processing of soluble rFel d 1.
Purification of Natural and Recombinant Fel d 1
rFel d 1 was purified in 2 steps: (1) hydrophobic
interaction chromatography, using a phenyl-sepharose col-
umn; (2) ion-exchange chromatography, using a MonoQ 5/50
GL column (both GE Healthcare Biosciences AB, Uppsala,
Sweden). The rFel d 1–containing fractions were pooled,
dialyzed against PBS, and concentrated (sixfold), and purity
of the sample was assessed by SDS-polyacrylamide gel
electrophoresis (SDS-PAGE). Natural Fel d 1 (nFel d 1) was
affinity-purified using monoclonal antibody (mAb) 4F7 as
previously described.1 Protein concentration was measured
by the BCA method27 (Pierce, Rockford, IL) as described by
the manufacturer.
For all experiments E. coli–derived rFel d 1 was used
unless indicated otherwise.
Murine Monoclonal Antibodies
MAb 4F7 to nFel d 1 was obtained as described by de
Groot et al.6 MAbs 6B4 and 10F10 against reduced/alkylated
nFel d 1 were obtained as described by van Milligen et al.28
MAb 6B4 had been shown to be specific for the light chain
and 10F10 for the heavy chain.
SDS-PAGE and Immunoblotting
SDS-PAGE and immunoblotting were performed as
described previously.29
Glutaraldehyde Modification of rFel d 1
Glutaraldehyde modification was done similarly for
both recombinant preparations. Purified rFel d 1 (5 mL of
1.055 mg/mL from E. coli) was dialyzed on a 1-kDa Amicon
membrane with 100 mM sodium carbonate (pH 9.0). The
residue was collected and diluted in the same buffer to 21
mL, resulting in a protein concentration of 0.250 mg/mL
(13.9 M, representing a total amount of 292 nmol); 1.37 mL
of 25% glutaraldehyde (Merck, Darmstadt, Germany) was
slowly added (final amount, 3.26 mmol). As rFel d 1 contains
12 lysine residues and glutaraldehyde has 2 aldehyde groups,
the molar ratio aldehyde/rFel d 1 is 1860. The mixture was
gently stirred overnight at room temperature; 6.54 mmol of
glycine was added in a time span of 30 minutes to quench
remaining free aldehyde groups. The mixture was stirred for
1 hour and dialyzed on a 10-kDa Amicon membrane. Protein
was not measured in the final product because reliable results
cannot be obtained for highly aggregated structures. For
further analysis it was assumed that the modification proce-
dure did not result in significant losses. A correction was
applied to account for dilution of the sample.
Online High-Performance Size-Exclusion
Chromatography Light Scattering
Online high-performance size-exclusion chromatogra-
phy (HPSEC) light scattering was performed using a 7.8 
300 mm TSKgel G2000SWXL column (Tosoh Bioscience,
Stuttgart, Germany) in single-column mode on a HP1100
analytical chromatography system (Hewlett-Packard, San
Jose, CA) equipped with a built-in UV detector and a sequen-
tial refractive index (RI), intrinsic viscosity (IV), and right-
angle light-scattering detection (TDA 302, Viscotek Corp.,
Houston, TX) as previously described.30
Rabbit Antisera
Two female New Zealand white rabbits were immu-
nized and boosted 5 times at 4-week intervals with 100
g/mL glutaraldehyde-modified rFel d 1 (rFel d 1-mod) from
P. pastoris. For each immunization, 1 mL of rFel d 1-mod
was mixed with 1 mL of Montanide ISA-50 (Seppic, Paris).
Radioallergosorbent Test
For measurement of specific IgE or IgG against nFel d
1, rFel d 1, and rFel d 1-mod, a radioallergosorbent test
(RAST) was performed as described previously.31 For IgE,
the results were expressed as IU/mL, and for IgG, the results
were expressed in % bound activity.
ImmunoCAP Inhibition
ImmunoCAP (Phadia, Uppsala, Sweden) was per-
formed according to the manufacturer’s instructions. For
CAP-inhibition, a serum pool of cat-allergic patients (n 
100) was preincubated at room temperature for 1 hour with
serial dilutions of inhibitor, before addition to cat Immuno-
CAP (e1). The following inhibitors were used: nFel d 1, rFel
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d 1, and rFel d 1-mod. Results were expressed as percentages
of inhibition.
Competitive Radioimmunoassay
To quantify Fel d 1 in different samples, a competitive
radioimmunoassay (RIA) or sandwich enzyme-linked immu-
nosorbent assay (ELISA) were used. The competitive RIA
was performed essentially as described elsewhere.32 The
Fel d 1 concentration was calculated by using the standard
curve of a house dust extract with known Fel d 1 content
(14 U/mL). One unit was considered to be equivalent to 1
g of Fel d 1.
The sandwich ELISA was developed by Chapman et
al33 (Indoor Biotechnologies, Warminster, UK). Serial sam-
ple dilutions were assayed. Reference Fel d 1 standard (9.7
U/mL) was used at serial dilutions from 20 to 0.04 mU/mL.
Plates were read in an ELISA microplate reader at 405 nm.
Stripped Basophil Histamine Release Bioassay
To assess biologic activity of Fel d 1, the stripped
basophil histamine release (BHR) bioassay was performed.
White blood cells were isolated from whole blood of a
nonallergic donor by Percoll centrifugation and stripped from
IgE by lactic acid treatment as described elsewhere.34,35
Subsequently, cells were resensitized with the patient’s serum
(n  4). Histamine release was performed with nFel d 1, rFel
d 1, and rFel d 1-mod (of 0.01 pg/mL to 100 g/mL).
Liberated histamine was measured by the fluorometric anal-
ysis essentially as described by Siraganian.36
Allergen-Specific Proliferation of Freshly
Isolated Peripheral Blood Mononuclear Cells
T-cell reactivity was assessed by measuring prolifera-
tion of peripheral blood mononuclear cells (PBMCs) from
cat-allergic donors to nFeld 1, rFel d 1, and rFel d 1-mod.
PBMCs were plated out at 2  105 cells per well in IMDM
(Bio-Whittaker, Walkersville, MD) supplemented with 5%
normal human serum (Bio-Whittaker) and gentamycin (80
g/mL; Duchefa, Haarlem, The Netherlands). Dilution series
of allergen or allergoid (0.03–10 g/mL) were added at day
0, followed by addition of 3H-labeled thymidine at day 6 and
harvesting of the radioactively labeled cells at day 7 to
measure the Ag-induced proliferation.
RESULTS
Production, Purification, and Modification
of rFel d 1
Constructs encompassing both chains of Fel d 1, either
directly linked together (E. coli) or using a linker sequence
(P. pastoris), were successfully developed. Expression level
in E. coli after 5 hours induction at 30°C was 43 g/mL as
determined by competitive RIA. In P. pastoris, 400 g/mL
was reached. rFel d 1 was purified by hydrophobic interaction
chromatography and ion-exchange chromatography, giving a
final yield of 92% from E. coli and purification efficacy was
similar from yeast. SDS-PAGE (Fig. 1) of nFel d 1 under
reducing conditions revealed one discrete band with an ap-
parent molecular weight of approximately 4.5 kDa and a
smear between 10 and 16 kDa. For rFel d 1 from P. pastoris,
5 bands (5, 7, 10, 17, and 20 kDa) and 2 smears (12–15 and
23–28 kDa) were observed, whereas rFel d 1 from E. coli
gave a single discrete band (molecular weight 17 kDa).
Glutaraldehyde modification of E. coli–derived rFel d 1
revealed 2 smears with an apparent molecular weight of
12–20 and 29–40 kDa, respectively.
N-Terminal sequencing of the 17 and 20 kDa bands
from rFel d 1 (P. pastoris) demonstrated that the lower
band is rFel d 1 with the correct N-terminal sequence
(EICPAVKRDV)10 and the upper band is rFel d 1 with 9
residual amino acids originating from the signal peptide,
upstream of the Kex 2 site (EEGVSLEKRE). N-Terminal
sequencing of the E. coli–derived 17-kDa band showed
that the first 10 amino acids were identical to the N-ter-
minal amino acid sequence (-chain) of Fel d 1 (VK-
MAETCPIF).10
Native and chemically modified rFel d 1 were charac-
terized regarding molecular size using small-angle x-ray
scattering and dynamic light-scattering methodologies, both
resulting in highly polydisperse mixtures of molecules (data
not shown). These mixtures were separated by HPSEC and
the values for molecular weight (MW) and hydrodynamic
radius (RH) of eluting fractions were determined by online
light scattering and viscosimetry (Fig. 2). The main fraction
of native Fel d 1 (representing 56% of the protein) was
determined to be 18kD, corresponding to monomeric Fel d
1. Small oligomers (MW 48 kD; RH 3.3 nm) represented
22% and larger oligomers (MW 85 kD; RH 5 nm) 16%
FIGURE 1. SDS-PAGE analysis of Fel d 1 preparations. SDS-
PAGE was performed under reducing conditions and silver-
stained. Lane 1, see blue plus marker (Invitrogen); lane 2,
nFel d 1; lane 3, rFel d 1 (P. pastoris); lane 4, rFel d 1; lane
5, glutaraldehyde-modified rFel d 1.
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of protein. In addition, 6% of highly aggregated protein
accounting for strong light-scattering intensity were de-
tected. Chemical modification of rFel d 1 caused formation
of polymers with a MW of 1 MDa. Three different major
fractions were found spanning large regions of the chro-
matogram.
Comparison of Immune Reactivity of Natural
and Recombinant Fel d 1
The IgE-binding characteristics of rFel d 1 were as-
sessed by RAST, immunoblot, and CAP-inhibition. Sera of
cat-sensitized patients (n  76) were tested in a RAST for
specific IgE antibodies against nFel d 1 and rFel d 1 (Fig. 3).
By Spearman rank correlation, IgE responses to nFel d 1 and
rFel d 1 were shown to closely correlate (Rs  0.9150 [95%
confidence interval (CI): 0.8680 to 0.9458]; P  0.0001).
Overall, binding to rFel d 1 was slightly higher than that to
nFel d 1 (mean ratio 1.3; 95% CI: 0.85–1.75). Five patients
were monosensitized to nFel d 1 (2 IU/mL), but with low
specific IgE titers and one was 5 times more reactive to
nFel d 1 than to the recombinant. On immunoblot IgE
reactivity to rFel d 1 was detected at 16 kDa, in some cases
accompanied by a faint band at 38 kDa, presumably rep-
resenting the rFel d 1 dimer (Fig. 4). MAb 4F7 raised to
purified nFel d 1 and both chain-specific mAbs bound to the
same 16-kDa band. MAb 6B4 (specific for the light -chain)
also detected the 38-kDa band, confirming the Fel d 1 nature
of this band. Comparing IgE-binding potencies of natural and
rFel d 1 with ImmunoCAP inhibition, using a serum pool of
cat-sensitized patients, demonstrated both preparations have
very similar inhibitory potencies (Fig. 5A). Additionally, the
biologic activity of both molecules assessed by BHR was
comparable (Fig. 5B). Competitive RIA with polyclonal rab-
bit antiserum against nFel d 1 and 125I-labeled nFel d 1 (Fig.
5C) further confirmed the similarity. Only the sandwich
ELISA based on 2 mAbs showed preference for nFel d 1 by
a factor of 6 (Fig. 5D). Overall, rFel d 1 is a good mimic of
its natural counterpart. Comparable results were obtained
with yeast-derived rFel d 1 (not shown).
Modified rFel d 1: Reduced IgE and IgG
Antibody Binding
Glutaraldehyde-modified rFel d 1 was evaluated by
CAP-inhibition, competitive RIA and ELISA. The IgE-bind-
ing potency in CAP-inhibition was reduced by 3 orders of
FIGURE 2. Determination of molecular size under physio-
logic conditions. Refractive index signal (bold lines) and MW
for native (black) and modified (gray) rFel d 1 determined
from online HPSEC light scattering. Determined MW values
of the eluting fractions (native: vret  5.6–7.3, 7.6–7.8, and
8.6–8.9 mL; modified: vret  5.6–6.8, 7.2–7.4, and 8.0–8.3
mL) are shown in thin dashed lines.
FIGURE 3. Comparison of IgE binding of natural versus re-
combinant Fel d 1. IgE responses to nFeld 1 (x-axis) were
compared with rFel d 1 (y-axis) by RAST using sera of 76
cat-allergic patients. Results are expressed in IE/mL. De-
creased reactivity toward rFel d 1 was observed for (5 of 76)
sera. The filled circles are exclusively positive for nFel d 1
and the filled triangle was 5 times more reactive to nFel d1
than to rFel d 1.
FIGURE 4. Immunoblotting of purified rFel d 1. Lanes 1–3
were detected with 3 Fel d 1–specific mAbs (4F7, 10F10,
and 6B4, respectively); lanes 4 and 5 were recognized by
sera derived from 2 cat-allergic patients (sera 6 and 154);
and lanes 6 and 7 were detected with rFel d 1-mod–specific
rabbit-polyclonal antibody (rabbit 140662 and 140831, re-
spectively).
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magnitude (1300-fold) compared with that of the unmodi-
fied recombinant allergen (Fig. 5A). Although the magnitude
of reduction observed in competitive RIA (Fig. 5C) and
ELISA (Fig. 5D) was not identical (500- and 5000-fold,
respectively), it was in both cases highly significant. Similar
results were obtained with yeast-derived rFel d 1 (not shown).
Modified rFel d 1: Reduced Biologic Activity
The biologic activity of rFel d 1-mod was assessed by
the stripped basophil histamine release bioassay (n  4). In a
first experiment, modified rFel d demonstrated 1000-fold
reduced reactivity compared with unmodified rFel d 1, but an
accurate assessment was not possible because the native
allergen was not diluted far enough (not shown). In a fol-
low-up experiment, for 2 of the 4 original sera, native
allergen was diluted up to 0.01 pg/mL, allowing a more
accurate calculation. rFel d 1-mod showed a decrease in
biologic activity of106-fold (Fig. 5B). Significant reduction
(1000-fold) was observed for yeast-derived rFel d 1-mod (not
FIGURE 5. Immunologic char-
acterization of modified rFel d
1. A, ImmunoCAP inhibition.
ImmunoCAP inhibition was per-
formed with a cat epithileum
and dander CAP (e1) and a se-
rum pool of 100 cat-allergic
patients. B, Stripped basophil
histamine release assay. C,
Competitive RIA. D, Fel d 1–spe-
cific sandwich ELISA. E, IgG
RAST. Symbols used: nFel d 1
(E), rFel d 1 (F), and rFel d
1-mod (f).
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shown). The stripped cells (negative control) showed a re-
lease of 4% (not shown).
Modified rFel d 1: Retained T-Cell Proliferation
PBMCs from 4 cat-allergic patients were stimulated
with dilutions of nFel d 1, rFel d 1, and rFel d 1-mod (Fig. 6).
The mean stimulation index at 10 g/mL was significantly
higher upon stimulation with modified allergen (8.4) com-
pared with the native molecule (5.6) (p(Wilcoxon)  0.01).
These data demonstrate that rFel d 1-mod had retained its
capacity to trigger cat allergen-specific T-cells. Similar ob-
servations were made for the yeast-derived recombinant mol-
ecule (not shown).
Immunogenicity of Modified rFel d 1
To assess the capability of rFel d 1-mod to induce
IgG antibodies recognizing the natural allergen, 2 rabbits
were immunized with the modified allergen from yeast.
The resulting rabbit antisera were tested in RAST and
immunoblot experiments for IgG reactivity with nFel d 1,
rFel d 1, and rFel d 1-mod. IgG antibodies induced upon
immunization with rFel d 1-mod bound in a similar fashion
to nFel d 1, rFel d 1, and rFel d 1-mod (Fig. 5E). Both
antisera also clearly detected unmodified rFel d 1 on
immunoblot (Fig. 4).
DISCUSSION
In past years, several strategies have been evaluated in
our laboratory to express rFel d 1, starting with separate
expression of both chains of the molecule in P. pastoris
(unpublished data), and subsequently, expression of both
chains coupled by a linker sequence (this study). In our
hands, this approach resulted in a rFel d 1 preparation with
good immune reactivity but an undesirable degree of molec-
ular heterogeneity caused by hyperglycosylation of a fraction
of the molecules at the N-linked glycosylation site in the
-chain of Fel d 1. Additionally, some instability of the linker
sequence resulted in partial cleavage of the two-chain het-
erodimer (confirmed by N-terminal sequencing of the
resulting fragments). Both post-translational modifications
did not significantly affect immune reactivity but the
observed heterogeneity is less favorable from a production
standpoint. A mutant lacking the N-linked glycosylation
site showed decreased heterogeneity, but was still partially
cleaved (not shown). Therefore, we chose to express rFel
FIGURE 6. Allergen-specific
proliferation of PBMCs. PBMCs
from 4 cat-allergic patients were
stimulated with dilutions of nFel
d 1 (E), rFel d 1 (F), and rFel d
1-mod (f). Panels A–D each
represent an individual patient.
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d 1 as a heterodimer of both chains without the instable
linker in E.coli resulting in a stable nonglycosylated ho-
mogeneous preparation.
Glutaraldehyde modification of this molecule resulted
in a truly hypoallergenic molecule with a reduction in IgE-
binding potency of around 1000-fold. This translated into a
negligible biologic activity (106-fold reduction). To our
knowledge this is unmatched by any hypoallergenic strategy
using site-directed mutagenesis.
The size distribution in solution demonstrated that
modification resulted in a molecular weight 1000 kDa.
However, under the denaturating conditions of SDS-PAGE,
part of the rFel d 1-mod migrated at an apparent molecular
weight of 12–20 and 29–40 kDa, indicating that not all
aggregation observed in solution was caused by conalent
interactions. This suggests that glutaraldehyde modification
results in polymerized and aggregated molecules of high MW
that may trap also monomers and low MW oligomers, which
can be released under reducing and denaturating conditions.
Although the mechanism of allergen-specific immuno-
therapy is still a matter of debate, it is clear that successful
therapy is accompanied by induction of regulatory T-cells
and IgG4 antibodies.37 It is generally accepted that a novel
immunotherapy product should have the potency to trigger
allergen-specific T-cells. Modified rFel d 1 was shown to
induce at least similar T-cell proliferation as its unmodified
counterpart. Additionally, a role in immunotherapy of IgG4 as
blocking antibodies is likely and we demonstrated that im-
munization of rabbits with modified rFel d 1 induced specific
IgG antibodies that were able to bind to native Fel d 1.
In summary, it was convincingly demonstrated that
chemical modification of a recombinant allergen is an easy
and highly effective way to achieve hypoallergenicity. This
approach will allow safe administration of higher doses of
allergen to achieve better efficacy.
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